Nicotinic acid (Niacin, Vitamin B3) is a water-soluble vitamin and a lipid-modifying agent. At therapeutic doses (250mg and above), it acts as an antihyperlipidemic drug, significantly reducing serum triglycerides, LDL cholesterol, and lipoprotein(a), while increasing HDL cholesterol. It is also essential for NAD/NADP coenzyme systems involved in cellular metabolism. In the Indian context, it is widely used for dyslipidemia management, often in combination with statins, and for the treatment of pellagra.
Adult: Dyslipidemia (IR): Initiate at 100-250 mg once or twice daily with meals. Titrate gradually over weeks to a therapeutic dose of 1.5-3 g/day in 2-3 divided doses. Common maintenance: 500 mg to 1 g twice daily. Pellagra: 100-500 mg/day in divided doses.
Note: Take with or immediately after a low-fat meal or snack to minimize gastrointestinal upset and flushing. Swallow tablet whole with a full glass of water. For flushing management, take a non-enteric coated aspirin (325 mg) 30 minutes prior. Avoid hot drinks or alcohol around dose time as they can exacerbate flushing.
Nicotinic acid's lipid-modifying effects are multifactorial and not fully understood. It potently inhibits hormone-sensitive lipase in adipose tissue, reducing the breakdown of triglycerides and the release of free fatty acids (FFA) into circulation. The reduced FFA flux to the liver decreases hepatic synthesis of triglycerides and the secretion of VLDL particles. Since LDL is a catabolic product of VLDL, LDL levels also fall. It uniquely increases HDL-C by reducing the hepatic catabolism of apolipoprotein A-I, the major protein component of HDL.
Pregnancy: Category C (US FDA). Adequate and well-controlled studies in pregnant women are lacking. Use only if potential benefit justifies potential risk to the fetus. Required for treatment of pellagra in pregnancy. High-dose lipid-lowering therapy is generally avoided.
Driving: May cause dizziness, lightheadedness, or hypotension. Patients should not drive or operate machinery until they know how the medication affects them, especially during initial titration.
| HMG-CoA Reductase Inhibitors (Statins: Atorvastatin, Simvastatin, Rosuvastatin) | Increased risk of myopathy and rhabdomyolysis. Mechanism: Additive skeletal muscle toxicity. | Major |
| Aspirin (low-dose) / NSAIDs | Aspirin can reduce severity of niacin flush by inhibiting prostaglandin synthesis. However, combined use with high-dose NSAIDs may increase GI ulcer risk. | Moderate |
| Bile Acid Sequestrants (Colestyramine, Colestipol) | Reduced absorption of nicotinic acid if taken simultaneously. Administer nicotinic acid at least 4-6 hours before or after the resin. | Moderate |
| Antihypertensives (especially Vasodilators, Alpha-blockers) | Additive hypotensive effect, leading to dizziness and syncope. | Moderate |
| Antidiabetic Agents (Insulin, Sulfonylureas, Metformin) | Nicotinic acid can increase blood glucose levels, reducing glycemic control. Dose adjustment of antidiabetics may be needed. | Moderate |
| Alcohol | Potentiates flushing and pruritus. Increases risk of hepatotoxicity. | Major |
Same composition (Nicotinic acid (250mg)), different brands: